# GHK-Cu Dosage in Research: Doses, Routes, and Half-Life Studied

> GHK-Cu dosage as studied, not prescribed: fibroblast collagen at 10⁻¹² to 10⁻⁹ M, topical 0.05–2%, rodent IP and intranasal protocols, and why no validated human half-life exists. Research-context only.

The concentrations, routes, and stability conditions reported in published work — described as study parameters, never as a human protocol.

## GHK-Cu dosage in research: concentrations and routes studied

GHK-Cu dosage in the research literature spans cell-culture concentrations and animal protocols, and nothing here is a human dosing recommendation. In fibroblast culture, collagen synthesis was studied across 10⁻¹² to 10⁻⁹ M, with onset at 10⁻¹² to 10⁻¹¹ M and a peak near 10⁻⁹ M [1]. Topical cosmetic and clinical formulations have been studied at roughly 0.05% to 2% (w/w) in creams, serums, and gels.

Animal systemic studies used routes and amounts specific to each model: intraperitoneal dosing in mouse pulmonary and silicosis models, oral gavage in mouse colitis, and intranasal dosing in aging and cognition studies. The human hair-loss RCT applied a 5-ALA + GHK topical complex at 50–100 mg/mL to the scalp [4]. These are documented study parameters — species, route, and concentration — not protocols for use.

## Half-life and pharmacokinetics in research

No rigorous human pharmacokinetic half-life has been published for GHK-Cu. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases; a rat HPLC study documented GHK being rapidly metabolized to the dipeptide histidyl-lysine after intravenous dosing [11]. Secondary literature cites a short systemic elimination on the order of one to two hours, with the copper-chelated complex being more stable than free GHK.

Topical behavior is different from systemic clearance. Rather than circulating and being cleared, applied GHK-Cu forms a dermal copper depot — about 97 ug/cm² retained over 48 hours in a human skin-penetration study [5] — giving prolonged local availability at the application site. For sourcing purposes, the takeaway is blunt: injectable or systemic GHK-Cu dosing protocols circulated in community contexts have no peer-reviewed human pharmacokinetic basis.

## Stability and formulation conditions

Stability is where the chemistry becomes a practical sourcing signal. The GHK-Cu complex has a very high copper stability constant (log K ~16.4) and is most stable near pH 5–6.5 at a 1:1 copper-to-peptide ratio [6]. The blue-violet color of a reconstituted solution is the expected copper(II) absorption and indicates an intact complex; a brown or green shift indicates oxidation or precipitation.

The incompatibilities are specific. Strong reducing agents — ascorbic acid below about pH 3.5 — reduce Cu(II) and break the complex, and AHAs, BHAs, and other low-pH actives can destabilize it or compete for copper. Because free GHK is highly hydrophilic (clogP -2.24), passive skin penetration is limited; palmitoylation (Pal-GHK, clogP ~1.14), liposomal encapsulation, ionic-liquid microemulsions, and microneedle pretreatment are the documented strategies to improve delivery [14].

---

A field guide to the copper-tripeptide record, read with a buyer's skepticism — every number tied to its source, every gap left visible, and nothing here sold, prescribed, or dispensed.